Table 1.

rhNGF enhances pain during injections of BAM8–22, β-ALA and ET-1.

	BAM8–22		β-ALA		ET-1
	Saline	NGF	Saline	NGF	Saline	NGF
Day 3	0.34 ± 0.20	1.14 ± 0.26	1.96 ± 0.51	1.73 ± 0.54	0.55 ± 0.17	0.77 ± 0.29
Day 21	0.61 ± 0.22	1.83 ± 0.42*	1.39 ± 0.49	3.06 ± 0.58*	0.50 ± 0.20	0.94 ± 0.36
Day 49	0.82 ± 0.25	1.23 ± 0.39	0.78 ± 0.33	0.56 ± 0.24	0.34 ± 0.20	1.46 ± 0.35*

Maximum pain recorded on a numeric rating scale (NRS, 0–10) in response to injections of BAM8–22, β-ALA, and ET-1 at 3 days (n = 11), 21 days (n = 9) and 49 days (n = 11; n = 8 for β-ALA) post rhNGF and saline administration, respectively.

Values are given as mean ± standard error (SEM), asterisks indicate significant differences between rhNGF and saline (p < 0.02).